News

02.20.18

Press Release

Achieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study

BOTHELL, Washington and VANCOUVER, British Columbia, February 20, 2018 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced preliminary data from their Phase I/II multi-dose, pharmacokinetic and pharmacodynamics (PK/PD) clinical study of cytisine. The study, initiated in October 2017,…

/Read More

01.24.18

Press Release

Achieve Announces Expansion of Partnership with the University of Bristol for Next Generation Cytisine-Based Therapies to Include Exclusive Rights for Cytisine Development Across Multiple Therapeutic Categories

BOTHELL, Washington and VANCOUVER, British Columbia, Jan. 24, 2018 /PRNewswire/ — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced an amendment to their Technology Licence Agreement with the University of Bristol, United Kingdom. Achieve has been granted exclusive rights for…

/Read More

11.28.17

Press Release

Achieve Announces Clinical Trial Supply and Cooperation Agreement with the University of Auckland for the Evaluation of Cytisine Compared to Varenicline for Smoking Cessation

BOTHELL, Wash and VANCOUVER, British Columbia, Nov. 28, 2017 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced an agreement with Auckland UniServices Limited, as the commercial arm of the University of Auckland, to provide cytisine for use in…

/Read More

11.14.17

Press Release

Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability of Cytisine in Fed and Fasted Subjects

BOTHELL, Wash and VANCOUVER, British Columbia, NOV. 14, 2017 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced results of a clinical study evaluating the effect of food on the bioavailability of 3mg cytisine. The study evaluated the bioavailability…

/Read More

11.08.17

Press Release

Achieve to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28th, 2017

BOTHELL, Wash and VANCOUVER, British Columbia, November 8, 2017 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that Rick Stewart, Chairman and Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference being held on…

/Read More